Respiratory therapy

CytoReason Collaborates with Sanofi, Using its AI Technology to Gain Better Understanding of Disease Mechanisms

Retrieved on: 
Thursday, June 17, 2021
Respiratory therapy, Health, Asthma, Sanofi

For this project, CytoReason's AI platform will use one of the most comprehensive datasets in moderate to severe asthma, covering samples from both adults and children.

Key Points: 
  • For this project, CytoReason's AI platform will use one of the most comprehensive datasets in moderate to severe asthma, covering samples from both adults and children.
  • Though symptoms of the disease can often be controlled, asthma, which is a key area of research for Sanofi, cannot be completely cured.
  • One of the main challenges in the disease is classification of patients to find the most suitable treatment.
  • "We are very excited to be launching our collaboration with Sanofi," said David Harel, CEO and Co-founder of CytoReason.

Inovytec & UAE's Healthsoft Partner to Sign Strategic Distribution Agreement for Ventway Sparrow Ventilators

Retrieved on: 
Thursday, June 17, 2021
Respiratory therapy, Ventilator

The Ventilators also received MOHAP approval to market in the UAE in the process of making the agreement.

Key Points: 
  • The Ventilators also received MOHAP approval to market in the UAE in the process of making the agreement.
  • "We chose Inovytec due to their ability to quickly meet the UAE market's needs with high-quality ventilators," said Ahmad Al Haj, Founder and CEO of Healthsoft.
  • Inovytec has created a number of innovative products to increase the chances of survivability for emergency victims and routine medical procedures.
  • The Ventway Sparrow family of portable, robust, high-performance ventilators are designed for in-hospital transport, emergency services, military medics, and homecare environments.

Inovytec & UAE's Healthsoft Partner to Sign Strategic Distribution Agreement for Ventway Sparrow Ventilators

Retrieved on: 
Thursday, June 17, 2021
Respiratory therapy, Ventilator

The Ventilators also received MOHAP approval to market in the UAE in the process of making the agreement.

Key Points: 
  • The Ventilators also received MOHAP approval to market in the UAE in the process of making the agreement.
  • "We chose Inovytec due to their ability to quickly meet the UAE market's needs with high-quality ventilators," said Ahmad Al Haj, Founder and CEO of Healthsoft.
  • Inovytec has created a number of innovative products to increase the chances of survivability for emergency victims and routine medical procedures.
  • The Ventway Sparrow family of portable, robust, high-performance ventilators are designed for in-hospital transport, emergency services, military medics, and homecare environments.

Pulmonary Fibrosis Foundation Launches New Website

Retrieved on: 
Wednesday, June 16, 2021
Lung disorders, Clinical medicine, Pulmonary rehabilitation, Respiratory therapy, Pulmonary fibrosis, Anatomy, Pulmonology

CHICAGO, June 16, 2021 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis education and advocacy organization, has launched a new website, pulmonaryfibrosis.org , for the more than 200,000 Americans impacted by pulmonary fibrosis (PF), a group of debilitating lung diseases.

Key Points: 
  • CHICAGO, June 16, 2021 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis education and advocacy organization, has launched a new website, pulmonaryfibrosis.org , for the more than 200,000 Americans impacted by pulmonary fibrosis (PF), a group of debilitating lung diseases.
  • The new website was funded through a grant from Three Lakes Foundation.
  • Patient resources on the new site include disease education videos and webinars, fact sheets on the types of pulmonary fibrosis, and a pulmonary rehabilitation toolkit.
  • The Pulmonary Fibrosis Foundation mobilizes people and resources to provide access to high-quality care and leads research for a cure so people with pulmonary fibrosis will live longer, healthier lives.

MannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI™ With New Drug Application Acceptance From the FDA

Retrieved on: 
Wednesday, June 16, 2021
Health sciences, MannKind Corporation, Thousand Oaks, California, Health care, Dosage forms, Respiratory therapy, United Therapeutics, Inhaler, Health, DPI, Daytona Prototype International

MannKind and United Therapeutics are also developing BluHale, a Bluetooth-connected accessory for the Tyvaso DPI inhaler with a companion mobile application intended to help patients track information about their inhaler use.

Key Points: 
  • MannKind and United Therapeutics are also developing BluHale, a Bluetooth-connected accessory for the Tyvaso DPI inhaler with a companion mobile application intended to help patients track information about their inhaler use.
  • MannKind and United Therapeutics entered into a worldwide exclusive licensing and collaboration agreement in September 2018 for the development and commercialization of Tyvaso DPI.
  • MannKind is entering an expansion phase as it prepares to transition from producing clinical supply to building pre-launch inventory of Tyvaso DPI, pending FDA approval.
  • Our site will practically double in size as we spend the next months preparing for Tyvaso DPI, pending FDA approval.

United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review

Retrieved on: 
Wednesday, June 16, 2021
Health sciences, Health care, Dosage forms, Respiratory therapy, Health, MannKind Corporation, Nebulizer, United Therapeutics, Dots per inch, Inhaler, DPI, Daytona Prototype International

If approved, Tyvaso DPI is expected to provide a more convenient method of administration compared with traditional nebulized Tyvaso therapy.

Key Points: 
  • If approved, Tyvaso DPI is expected to provide a more convenient method of administration compared with traditional nebulized Tyvaso therapy.
  • United Therapeutics is developing Tyvaso DPI under a collaboration and license agreement with MannKind Corporation (Nasdaq: MNKD).
  • United Therapeutics and MannKind are also developing BluHale, a Bluetooth-connected accessory for the Tyvaso DPI inhaler with a companion mobile application intended to help the patient track information about inhaler use.
  • Between-subject variability for both AUC0-5h and Cmax was approximately 50% less for Tyvaso DPI compared to Tyvaso Inhalation Solution, suggesting a more precise dosing profile for Tyvaso DPI relative to nebulized Tyvaso.

New Study Investigates the Impact of ORi-Guided Oxygen Titration on Hyperoxemia-Mediated Morbidity During One-Lung Ventilation

Retrieved on: 
Monday, June 14, 2021
Practice Management, Nursing, Surgery, General Health, Health, Medical devices, Hospitals, Clinical trials, Medicine, Clinical medicine, Health care, Cardiology, Medical monitoring, Pulse oximetry, Respiratory therapy, Oxygen therapy, Respiratory arrest, Masimo

Moreover, in our study, it was revealed that these patients had a longer hospital stay.

Key Points: 
  • Moreover, in our study, it was revealed that these patients had a longer hospital stay.
  • Oxygen Reserve Index Guided Oxygen Titration in One Lung Ventilation with Low Fresh Gas Glow.
  • Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns.
  • Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity.

Encore Healthcare Announces Staggering Results in New Nexus TeleRespiratory Care Pilot Using Data to Predict when Oxygen/Nebulizer Patients Need Non-Invasive Ventilation (NIV) Before Hospitalizations Happen

Retrieved on: 
Friday, June 11, 2021
Medicine, Health sciences, Clinical medicine, Respiratory therapy, Medical equipment, Dosage forms, Aerosols, Nebulizer, Oxygen, Oxygen therapy, Chronic obstructive pulmonary disease, Respiratory therapist

LIVINGSTON, Tenn., June 11, 2021 /PRNewswire/ --Encore Healthcare announces staggering results from their new oxygen and nebulizer management Nexus TeleRespiratory Care model.

Key Points: 
  • LIVINGSTON, Tenn., June 11, 2021 /PRNewswire/ --Encore Healthcare announces staggering results from their new oxygen and nebulizer management Nexus TeleRespiratory Care model.
  • In the initial pilot with a national HME provider Encore identified 12.5% of patients on oxygen/nebulizers needed additional services including medications, NIV and High Frequency Chest Wall Oscillation (HFCWO).
  • These results are an example of how data can drive better patient outcomes and revenue to HME providers at the same time.
  • The Nexus platform aligns HME respiratory providers across traditional boundaries while increasing provider productivity and clinical outcomes with their Ventilator/High-Risk COPD patients.

Global Asthma and COPD Devices Market 2021-2026: Transforming Healthcare Infrastructure in Emerging Markets - ResearchAndMarkets.com

Retrieved on: 
Friday, June 11, 2021
Medical devices, Health, Chronic lower respiratory diseases, Health, Respiratory therapy, Clinical medicine, Chronic obstructive pulmonary disease, Asthma

The "Asthma and COPD Devices Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asthma and COPD Devices Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The report predicts the global asthma and COPD devices market to grow with a CAGR of 4.7% over the forecast period from 2020-2026.
  • Comprehensive analysis of the global as well as regional markets of the asthma and COPD devices market.
  • Complete coverage of all the segments in the asthma and COPD devices market to analyze the trends, developments in the global market and forecast of market size up to 2026.

Rapid Therapeutic Finalizes Lab Work on Pharmaceutical Formulas

Retrieved on: 
Thursday, June 10, 2021
Drugs, Health sciences, Pharmacology, Dosage forms, Cannabinoids, Resorcinols, Asthma, Respiratory therapy, Cannabigerol, Metered-dose inhaler, Cannabidiol, Inhaler

RTSL has developed three (3) proprietary pharmaceutical formulas, two (2) for cannabidiol (CBD) and one (1) for cannabigerol (CBG), to initially be used in Metered Dose Inhalers (MDI).

Key Points: 
  • RTSL has developed three (3) proprietary pharmaceutical formulas, two (2) for cannabidiol (CBD) and one (1) for cannabigerol (CBG), to initially be used in Metered Dose Inhalers (MDI).
  • RTSLs CEO, Donal R. Schmidt, Jr. stated, We initially set out to find an ultra-pure, unadulterated pharmaceutical grade CBD isolate to use in our MDI.
  • We also learned CBD isolate is not chemically compatible with metered dose inhalers without significant modifications in the manufacturing process.
  • In short, we were unsatisfied with any product we could source in the hemp space to meet our needs.